Published on : Mar 07, 2017
ALBANY, NY, March 07, 2017: The research report, titled “Dermatology Therapeutics Drug Development Pipeline Review, 2016,” discusses the future of the dermatology therapeutics drug development industry. It analyzes the industry’s progress so far and offers projections for the coming years. The research report states that the pipeline for dermatology therapeutic drugs will be exceptionally innovative and will focus on commercializing bleeding edge technologies to treat a wide range of diseases and skin disorders. The research report includes comments and recommendations by market experts that points out important trends in the overall industry.
The dermatology therapeutics drug development pipeline is expected to grow at a phenomenal pace in the coming years due to a high prevalence of skin diseases and disorders. The industry has shown an emphasis on research and development of drugs for psoriasis, acne, and atopic dermatitis. Acne accounts of a major share in the overall market, which is followed by psoriasis and atopic dermatitis. The global market is projected to receive a major boost in the near future due to the upcoming patent expires. Thus, the growing pressure on companies to commercialize their drugs and therapeutics is expected to result in a flurry of new drugs in the market.
Click to get more details with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=984798
The therapeutic procedures studied in this research report are corticosteroids, anti-infectives, anti-psoriasis, topical and dermatological drugs, and anti-acne. The research report discusses the wave of biologics in treating skin disorders and conditions and its impact on the overall market. The publication states that increasing focus on aesthetics and cosmetics, growing popularity of skin care products, and affordability of therapeutics and drugs to treat skin conditions are likely to augment the development of dermatology therapeutics drug pipeline in the near future.
Geographically, the market is segmented into North America, Asia Pacific, Europe, and Rest of the World. Currently, North America lead the global market due to a high prevalence of skin disorders in the region and a growing awareness about diagnostics. Supportive government structures and improving reimbursement policies are also expected to favor market growth in the coming years.
Some of the leading players working on developing dermatology therapeutics drug development are Genentech Inc., AGI Dermatics, Amgen Inc, Allergan Inc, Dermik Laboratories Inc, Chester Valley Pharmaceuticals Inc, Eisai Inc., Medicis Pharmaceutical Corp, Ferndale Laboratories Inc., Onset Therapeutics, Prime Pharmaceuticals Corp, Sinclair Pharmaceuticals, Schering-Plough Corp, Skinmedica Inc., Valeant Pharmaceuticals International, and Summers Laboratories Inc among others. The research report provides a detailed understanding of the competitive landscape of the global market. It also explains the expansion plans of these companies, their business and marketing strategies, and an assessment of the kind of investments they are likely to make in the near future.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org